angiotensin II receptor type 2Genealiases: AT2 · ATGR2 · MRX88
Q-omics provides the consensus-scored AGTR2 profile across patient tissues and cancer cell-line models. AGTR2 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, AGTR2 is differentially expressed in 8, with the highest sampling consensus in LUAD. Additionally, AGTR2 RNA expression shows 12,601 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRP, LUAD, and LSCC as cancer lineages where AGTR2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for AGTR2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes AGTR2 survival associations across molecular data types. AGTR2 RNA expression shows survival associations in the most cancer types (17), followed by mutation status (9) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible AGTR2 RNA expression–survival associations across cancer types. High AGTR2 expression shows unfavorable associations in KIRP, HNSC, STAD and UVM, but favorable associations in BRCA and THCA. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for AGTR2 RNA expression.
This table summarizes AGTR2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for AGTR2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. AGTR2 shows lower tumor expression in LUAD, KIRP, LUSC, KICH, KIRC and COAD. The LUAD box plot shows higher AGTR2 RNA expression in normal versus tumor tissue (log2 FC = −4.213, t-test p < 0.001).
This table shows molecular features associated with AGTR2 in patient tissues and cancer cell lines. In patient samples, AGTR2 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, AGTR2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LUNG_SCLC.
